非小细胞肺癌治愈性多模式治疗:2017-2025变革时代
本文综述2017年以来II-III期非小细胞肺癌治愈性多模式治疗的变革,免疫治疗与靶向治疗已嵌入治愈性方案,形成多个新标准。作者提出新治疗流程算法,认为新辅助及围手术期化免联合是多数可手术患者的最佳路径。最大挑战在于选择、排序和交付复杂治疗及患者优化。
要点
- 不可切除III期放化疗后维持免疫治疗已成新标准。
- 可切除EGFR/ALK阳性肿瘤术后辅助TKI已成新标准。
- 可切除II/III期新辅助及围手术期化免联合已成新标准。
核心结论
- 免疫与靶向药物已不可逆地改变治愈性NSCLC治疗,建立多个有时重叠竞争的新标准。
- 可手术多模式路径中,新辅助及围手术期化免联合较辅助治疗可提高系统治疗 uptake,作者认为代表多数患者最佳路径。
- 当前最大挑战不再是缺乏有效治疗,而是选择、排序、交付及患者优化。
研究设计与样本
- 本文件为state-of-the-art综述,综合支持2017年以来治愈性多模式治疗发展的关键证据。
主要发现
- 免疫治疗和靶向治疗原限于晚期/转移 setting,现已牢固嵌入治愈性方案。
- 不可切除III期放化疗后维持免疫治疗、可切除EGFR/ALK阳性肿瘤辅助TKI、可切除II/III期新辅助及围手术期化免联合、术后辅助化免联合均成为新标准。
- 作者提出新治疗算法以支持临床医生导航复杂治疗选择。
关键数值与推荐
- 不可切除III期:放化疗后维持免疫治疗为新标准。
- 可切除EGFR/ALK阳性:术后辅助TKI为新标准。
- 可切除II/III期:新辅助及围手术期化免联合为新标准。
- 可切除:术后辅助化免联合为新标准。
临床怎么用
- 需重新定义临床路径、准确治疗前分期、及时生物标志物检测和协调多学科决策。
- 肺癌服务应通过主动路径重设计、整合诊断和新多学科护理模式演进。
- 高质量、生物标志物驱动和以患者为中心的护理对许多II-III期NSCLC患者可实现,但需系统层面适应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Curative-intent multimodality treatment-combining local treatments such as surgery or radiotherapy with systemic therapy-is the cornerstone of care in stage II-III non-small cell lung cancer (NSCLC). Since 2017, the systemic therapy backbones with multimodality treatment have undergone a dramatic transformation, driven by a series of pivotal, practice-changing clinical trials. Immunotherapy and targeted therapies, previously confined to the advanced/metastatic setting, are now firmly embedded in curative-intent regimens. Maintenance immunotherapy following chemoradiation in unresectable stage III disease, adjuvant tyrosine kinase inhibitors in resected epidermal growth factor receptor/anaplastic lymphoma kinase-positive tumours, neoadjuvant and perioperative chemoimmunotherapy in resectable stage II/III NSCLC and adjuvant chemoimmunotherapy following resection have all become new standards of care.This state-of-the-art review synthesises the key evidence underpinning these developments, highlights their clinical implications and identifies challenges to implementation-particularly the need for redefined clinical pathways, accurate pretreatment staging, timely biomarker testing and coordinated multidisciplinary decision-making. A novel treatment algorithm is proposed to support clinicians in navigating these complex treatment choices.We conclude that immunotherapy and targeted agents have irrevocably altered curative-intent NSCLC care, establishing multiple new standards that sometimes overlap and compete. In the surgical multimodality treatment pathway, neoadjuvant and perioperative chemoimmunotherapy offers the opportunity to increase the uptake of systemic therapy in comparison to adjuvant therapy and is considered by these authors to represent the optimal treatment path for most patients.In this unprecedented era of therapeutic expansion, the greatest challenge is no longer the absence of effective treatments, but the complexity of selecting, sequencing and delivering them, as well as patient optimisation. Lung cancer services must evolve through proactive pathway redesign, integrated diagnostics and new models of multidisciplinary care. High-quality, biomarker-driven and patient-centred care is now achievable for many patients with stage II-III NSCLC-but it will require system-level adaptation to deliver it.
引用
- Evison M, Ahmed T, Chitnis M, et al. Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017-2025. Thorax. 2026. PMID: 40912914. doi:10.1136/thorax-2025-223096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。